Antisense oligonucleotides targeting apo

1. Antisense oligonucleotides targeting apo decreases lipoprotein in humans.

   “Antisense oligonucleotides targeted to apo(a) are in Phase 2 clinical development and shown to lower both lipoprotein(a) and oxidized phospholipids.”

   Review

   Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis

   Current opinion in cardiology·1 Jul 2016

More on Lipoprotein